Loading
A phase 2 trial of SPH4336 in brain and spinal cord tumours, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.
Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. is a phase 2 interventional study registered as NCT05872347 by Shanghai Pharmaceuticals Holding Co., Ltd, with 52 participants planned, started 2023-09-19 and due to reach its primary completion in 2026-12-31. Interventions recorded: SPH4336 Tablets.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SPH4336, GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares Brain metastases (secondary brain tumours), Brain and spinal cord tumours (all types) and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares Brain metastases (secondary brain tumours), Brain and spinal cord tumours (all types) and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/